ABOUT THE COURSE

The HFSA Virtual Board Certification Review 2020 content is based on the ABIM content blueprint for the certification examination in Advanced Heart Failure and Transplant Cardiology. It will be held over the course of 3 days (July 24, July 31, August 1) and include pre-recorded on-demand webinars.

This activity will use concise didactic presentations by national experts, case studies, and panel discussions. An audience response system (ARS) will be utilized throughout all presentations and to deliver ABIM style questions in designated session time. Additional question and answer periods with faculty will enable attendees to drive the discussion according to their most pressing clinical challenges. A reading list compiled for the activity contains additional references regarding guideline- and evidence-based therapy.

The following areas are addressed:

- Epidemiology and Causes of Heart Failure
- Pathophysiology of Heart Failure
- Evaluation of Heart Failure
- Management of Hospitalized Patients
- Management of Heart Failure
- Comorbidities or Coexisting Conditions
- Cardiac Surgery in Heart Failure
- Heart Transplant
- Mechanical Circulatory Support
- Pulmonary Arterial Hypertension
- Contemporary HF Management Topics

ABIM CERTIFICATION DEADLINES

ABIM Certification Exam Date:
October 21, 2020

Registration Dates:
December 1, 2019 – June 15, 2020

Late Registration Dates:
June 16-28, 2020 (additional fees apply)

Visit www.abim.org for additional information about the certification exam.

PROGRAM COMPONENTS

The program will be made up of the following components to allow attendees greater access to the content.

PRE-RECORDED WEBINAR SERIES:
HEART FAILURE FUNDAMENTALS
Available in early July, this pre-recorded, on-demand webinar series features the basics and can be completed at the attendee’s convenience.

LIVESTREAM SESSIONS
Three, non-consecutive days of livestreamed sessions (July 24, July 31, August 1) delivered by top experts in the field. Attendees should anticipate being online throughout to receive maximum value from these live sessions. If a livestream session must be missed due to other circumstances, all livestream sessions will be available for attendees to download and access approximately two weeks after the meeting concludes. Full agenda is available at hfsa.org/boardreview2020/program

FACULTY “OFFICE HOURS”
Post-meeting, virtual livestream Q&A panel taking place in September to allow attendees to ask last-minute questions prior to the examination in October.

ADDITIONAL BONUS FEATURES
In addition to the core program components, attendees will have access to the following:

- A question bank
- Recommended reading list
- Live polling, Q&A, and chat features available during the livestream days
- Chat with fellow attendees and faculty throughout the course of the meeting

MEETING SUPPORTERS

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support this year’s HFSA Virtual Board Certification Review Course:

Abbott
Amgen
AstraZeneca
Medtronic
Merck
Relypsa
This HFSA Virtual Board Certification Review 2020 has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

**LEARNING OBJECTIVES**

Upon completion of the activity, participants will demonstrate improved competence and ability to:

**For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:**
1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
2. Focus study efforts on filling identified knowledge gaps
3. Practice for the certification examination with ABIM-style multiple-choice test questions

**For Clinical Practice:**
1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device

Concise presentations by national experts will focus on blueprint content and will be augmented by board-review-type questions posed using an audience-response system.
FACULTY

CO-CHAIRS

Akshay S. Desai, MD, MPH, FHFSAMedical Director, Cardiomyopathy and Heart Failure Program,Advanced Heart Disease SectionBrigham and Women’s HospitalBoston, MA

Jonathan Rich, MD, FHFSAAssociate Professor of MedicineNorthwestern University, Feinberg School of MedicineMedical Director, Mechanical Circulatory Support ProgramProgram Director, Advanced Heart Failure and Transplant FellowshipBluhm Cardiovascular Institute, Northwestern Memorial HospitalChicago, IL

Nancy Sweitzer, MD, PhD, FHFSAProfessor of MedicineChief of CardiologyDirector, Sarver Heart CenterUniversity of ArizonaTucson, AZ

Mark Drazner, MD, MSc, FHFSAClinical Chief of CardiologyMedical Director of the LVAD and Cardiac Transplantation ProgramProfessorUniversity of Texas Southwestern Medical CenterDallas, TX

James Fang, MD, FHFSAProfessor of MedicineChief, Division of Cardiovascular MedicineExecutive Director, Cardiovascular Service LineUniversity of UtahSalt Lake City, UT

Sadiya Khan, MD, MScAssociate Professor of Medicine – CardiologyAssociate Professor of Preventive Medicine – EpidemiologyNorthwestern University Feinberg School of MedicineChicago, IL

Michelle Kittleson, MD, PHDProfessor of MedicineDirector of Post Graduate Medical Education in Heart Failure and TransplantationDirector of Heart Failure ResearchCedars Sinai Medical CenterBeverly Hills, CA

Liviu Klein, MD, MSAssociate Professor of MedicineDivision of Cardiology, University of California San FranciscoDirector, Cardiology Clinical ResearchDirector, Mechanical Circulatory Support & Heart Failure Device ProgramUniversity of California, San FranciscoSan Francisco, CA

Eric Krieger, MDAssociate Professor of MedicineDirector, Seattle Adult Congenital Heart ServiceDirector, Adult Congenital Heart Disease FellowshipAttending Physician, University of Washington Medical CenterUniversity of Washington School of MedicineSeattle Children’s HospitalSeattle, WA

Meredith Brisco-Bacik, MD, MSCEAssociate Professor of MedicineDirector, Heart Failure Clinical ResearchAdvanced Heart Failure and Cardiac TransplantationThe Lewis Katz School of Medicine at Temple UniversityPhiladelphia, PA

Daniel Burkhoff, MD, PhD
Columbia University
New York, NY

Jennifer Cowger, MD, MS
Medical Director of Mechanical Circulatory Support ProgramCo-Director of the Cardiac Intensive Care UnitHenry Ford Hospitals, Detroit MichiganAssociate Professor, Wayne State UniversityDetroit, MI

Akshay S. Desai, MD, MPH, FHFSAMedical Director, Cardiomyopathy and Heart Failure Program,Advanced Heart Disease SectionBrigham and Women’s HospitalBoston, MA
Gregory Lewis, MD
Section Head, Heart Failure
Director, Cardiopulmonary Exercise Testing Laboratory
Medical Director, Cardiac Transplantation Program
Massachusetts General Hospital
Boston, MA

Jon Lomasney, MD
Associate Professor of Pathology
Associate Professor of Pharmacology
Feinberg School of Medicine of Northwestern University
Chicago, IL

Anju Nohria, MD, MSc
Associate Physician, Brigham and Women’s Hospital
Assistant Professor of Medicine, Harvard Medical School
Boston, MA

Sean Pinney, MD
Professor of Medicine
Co-Director of the Heart & Vascular Center
Director of Heart Failure & Transplantation and Director of Clinical & Translational Research
Director, Advanced Heart Failure and Transplantation Program
University of Chicago
Chicago, IL

Joseph Rogers, MD
Chief Medical Officer
Duke University Health System
Professor of Medicine – Cardiology
Duke University
Durham, NC

Sanjiv Shah, MD
Stone Professor of Medicine
Director of Research, Bluhm Cardiovascular Institute
Director, Northwestern HFpEF Program
Division of Cardiology, Department of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Nancy Sweitzer, MD, PhD, FHFSa
Professor of Medicine
Chief of Cardiology
Director, Sarver Heart Center
University of Arizona
Tucson, AZ

Jane Wilcox, MD, MSc, FHSA
Assistant Professor of Medicine
Director, Myocardial Recovery Program
Associate Director, T1 Center for Cardiovascular Therapeutics
Bluhm Cardiovascular Institute
Chicago, IL

Clyde W. Yancy, MD, MSc, FHSA
Vice-Dean, Diversity & Inclusion
Chief of Cardiology
Professor of Medicine
Professor, Medical Social Sciences
Associate Director
Bluhm Cardiovascular Institute
Deputy Editor, JAMA Cardiology
Chicago, IL
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 12 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

Meredith Brisco-Bacik, MD, MSCE
Mark Drazner, MD, MSc, FHFSA
Sadiya Khan, MD, MSc
Michelle Kittleson, MD, PHD
Eric Krieger, MD
Jon Lomasney, MD
Joseph Rogers, MD
Sanjiv Shah, MD

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

Daniel Burkhoff, MD, PhD – Research Grant: Abiomed (Education), Ancora Medical, Tenax, Fire 1; Ownership Interest: PV Loops LLC (non-relevant financial relationship); Consultant-Advisory Board: BackBeat Medical, CardioDyme, Janssen Pharmaceuticals, Medtronic, Axon THERAPIES; Corvia, PVLoops LLC

Jennifer Cowger, MD, MS – Research Grant: Abbott, Medtronic; Speaker-Honoraria: Abbott, Medtronic; Consultant-Advisory Board: Abbott, Medtronic

Akshay Desai, MD, MPH, FHFSA – Research Grant: Alnylam; AstraZeneca; Novartis; Consultant-Advisory Board: Abbott; Alnylam; AstraZeneca; Amgen; Biofourmis; Noston Scientific; Boehringer-Ingelheim; Corvidia; DalCor Pharma; Merck; Novartis; Relypsa; Regeneron

Liviu Klein, MD, MS – Consultant-Advisory Board: Boston Scientific (Steering Committee); Medtronic (Steering Committee)

Anju Nohria, MD, MSc – Research Grant: Amgen, Inc.; Consultant-Advisory Board: Takeda Oncology

Sean Pinney, MD – Speaker-Honoraria: CareDX; Consultant-Advisory Board: CareDx

Nancy Sweitzer, MD, PhD, FHFSA – Research Grant: Merck, Novartis; Consultant-Advisory Board: Myokardia

Jane Wilcox, MD, MSc, FHFSA – Speaker-Honoraria: Medtronic; Consultant-Advisory Board: Cytokinetics

Clyde Yancy, MD, MSc, FHFSA – Financial Disclosure: Spousal employment at Abbott, Inc.

Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
**HFSA VIRTUAL BOARD CERTIFICATION REVIEW 2020**

- Pre-Recorded Webinar Series: Heart Failure Fundamentals
- 2020 HFSA Board Certification Review Course – July 24, July 31-August 1, 2020
  - Day 1 | July 24 | 3:00 PM – 6:00 PM ET
  - Day 2 | July 31 | 11:00 AM - 6:00 PM ET
  - Day 3 | August 1 | 11:00 AM – 5:45 PM ET
- Faculty “Office Hours” Virtual Live-Stream Panel – September 2020 (TBD)

**PRE-RECORDED WEBINAR SERIES: HEART FAILURE FUNDAMENTALS**

<table>
<thead>
<tr>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Failure Epidemiology and Risk Factors</td>
<td>Sadiya Khan</td>
</tr>
<tr>
<td>Pathophysiology I: Cellular and Energetic Considerations</td>
<td>Daniel Burkhoff</td>
</tr>
<tr>
<td>Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations</td>
<td>Daniel Burkhoff</td>
</tr>
<tr>
<td>Diagnosis and Clinical Assessment</td>
<td>Mark Drazner</td>
</tr>
<tr>
<td>Device Therapy in Heart Failure</td>
<td>Liviu Klein</td>
</tr>
<tr>
<td>Cardio-Oncology for the HF boards</td>
<td>Anju Nohria</td>
</tr>
<tr>
<td>Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards</td>
<td>Jon Lomasney</td>
</tr>
</tbody>
</table>

**VIRTUAL LIVE-STREAM MEETING: DAY 1**

**July 24, 2020 | 3 PM - 6 PM EST**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM</td>
<td>2:00 PM</td>
<td>12:00 PM</td>
<td>Welcome &amp; HFSA Introduction</td>
<td>Akshay Desai; John Barnes</td>
</tr>
</tbody>
</table>

**SESSION I - Cardiac Transplantation**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>2:30 PM</td>
<td>12:30 PM</td>
<td>Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies</td>
<td>Nancy Sweitzer</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>3:00 PM</td>
<td>1:00 PM</td>
<td>Immunology: The Basics, PRA, Sensitization, Crossmatch</td>
<td>Sean Pinney</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>3:30 PM</td>
<td>1:30 PM</td>
<td>Rejection: Cellular and Antibody Mediated</td>
<td>Sean Pinney</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>4:00 PM</td>
<td>2:00 PM</td>
<td>Managing Immunosuppression and Drugs</td>
<td>Michelle Kittleson</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>4:30 PM</td>
<td>2:30 PM</td>
<td>Heart Transplant, Clinical Outcomes and Complications</td>
<td>Michelle Kittleson</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>5:00 PM</td>
<td>3:00 PM</td>
<td>Adjourns</td>
<td></td>
</tr>
</tbody>
</table>
## VIRTUAL LIVE-STREAM MEETING: DAY 2

**July 31, 2020 | 11 AM - 6 PM EST**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>10:00 AM</td>
<td>8:00 AM</td>
<td>Welcome</td>
<td>Akshay Desai</td>
</tr>
</tbody>
</table>

### SESSION II: Key Issues in HF Management

**Moderator: Jonathan Rich**

<table>
<thead>
<tr>
<th>Time</th>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 AM</td>
<td>10:30 AM</td>
<td>8:30 AM</td>
<td>Hemodynamics in HF I</td>
<td>James Fang</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>11:00 AM</td>
<td>9:00 AM</td>
<td>Hemodynamics in HF II</td>
<td>James Fang</td>
<td></td>
</tr>
<tr>
<td>12:30 PM</td>
<td>11:30 AM</td>
<td>9:30 AM</td>
<td>Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)</td>
<td>Clyde Yancy</td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>12:00 PM</td>
<td>10:00 AM</td>
<td>Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)</td>
<td>Mark Drazner</td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td>12:30 PM</td>
<td>10:30 AM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:45 PM</td>
<td>12:45 PM</td>
<td>10:45 AM</td>
<td>HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)</td>
<td>Sanjiv Shah</td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td>1:15 PM</td>
<td>11:15 AM</td>
<td>Management of the Hospitalized HF Patient</td>
<td>Meredith Brisco-Bacik</td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>1:45 PM</td>
<td>11:45 AM</td>
<td>Management of Common Arrhythmias in HF (including AF)</td>
<td>Liviu Klein</td>
<td></td>
</tr>
<tr>
<td>3:15 PM</td>
<td>2:15 PM</td>
<td>12:15 PM</td>
<td>Management of Comorbidities in Heart Failure</td>
<td>Meredith Brisco-Bacik</td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td>2:45 PM</td>
<td>12:45 PM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION III: Specific Heart Failure Syndromes

**Moderator: Jonathan Rich**

<table>
<thead>
<tr>
<th>Time</th>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 PM</td>
<td>3:00 PM</td>
<td>1:00 PM</td>
<td>Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)</td>
<td>Akshay Desai</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td>3:30 PM</td>
<td>1:30 PM</td>
<td>Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)</td>
<td>Jane Wilcox</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>4:00 PM</td>
<td>2:00 PM</td>
<td>Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)</td>
<td>Sanjiv Shah</td>
<td></td>
</tr>
</tbody>
</table>

### Q&A Panel I

<table>
<thead>
<tr>
<th>Time</th>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 PM</td>
<td>4:30 PM</td>
<td>2:30 PM</td>
<td>Q&amp;A ---- Overview</td>
<td>Chairs</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td>5:00 PM</td>
<td>3:00 PM</td>
<td>Adjourns</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

HFSA VIRTUAL BOARD CERTIFICATION REVIEW 2020

Advanced Heart Failure & Transplant Cardiology

www.hfsa.org
## VIRTUAL LIVE-STREAM MEETING: DAY 3

**August 1, 2020 | 11 AM - 5:45 PM EST**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>10:00 AM</td>
<td>8:00 AM</td>
<td>Welcome &amp; Q/A</td>
<td>Akshay Desai</td>
</tr>
<tr>
<td><strong>SESSION IV - Shock/MCS</strong></td>
<td><strong>Moderator: Nancy Sweitzer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>10:30 AM</td>
<td>8:30 AM</td>
<td>Cardiogenic Shock Management</td>
<td>Nancy Sweitzer</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>11:00 AM</td>
<td>9:00 AM</td>
<td>MCS I: Durable MCS Devices and Outcomes</td>
<td>Joseph Rogers</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>11:30 AM</td>
<td>9:30 AM</td>
<td>MCS II: Temporary Support Devices and ECMO for the Boards</td>
<td>Jennifer Cowger</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>12:00 PM</td>
<td>10:00 AM</td>
<td>MCS III: MCS Complications and Patient Management</td>
<td>Jennifer Cowger</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>12:30 PM</td>
<td>10:30 AM</td>
<td>MCS IV: Troubleshooting (with HARVI)</td>
<td>Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>1:30 PM</td>
<td>11:30 AM</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION V: Special Topics in HF</strong></td>
<td><strong>Moderator: Akshay Desai</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>1:45 PM</td>
<td>11:45 AM</td>
<td>Assessment of Functional Capacity including cardiopulmonary exercise testing</td>
<td>Gregory Lewis</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>2:15 PM</td>
<td>12:15 PM</td>
<td>Adult Congenital Heart Disease for the HF Specialist</td>
<td>Eric Krieger</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>2:45 PM</td>
<td>12:45 PM</td>
<td>Issues in Chronic HF Disease Management</td>
<td>Akshay Desai</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>3:15 PM</td>
<td>1:15 PM</td>
<td>Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)</td>
<td>Jane Wilcox</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>3:45 PM</td>
<td>1:45 PM</td>
<td>Pulmonary Hypertension</td>
<td>Jonathan Rich</td>
</tr>
</tbody>
</table>

**Q&A Panel II**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:15 PM</td>
<td>4:15 PM</td>
<td>2:15 PM</td>
<td>Q&amp;A ---- Overview</td>
<td>Chairs</td>
</tr>
<tr>
<td>5:45 PM</td>
<td>4:45 PM</td>
<td>2:45 PM</td>
<td>Adjourns</td>
<td></td>
</tr>
</tbody>
</table>

### Faculty “Office Hours” Virtual Live-Stream Panel

**September 4, 2020**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBD</td>
<td>TBD</td>
<td>TBD</td>
<td>Special Office Hour - Q&amp;A</td>
<td>Akshay Desai, Nancy Sweitzer, Jonathan Rich</td>
</tr>
</tbody>
</table>